

**INTERIM REPORT
for I-VI 2014
Group Medika**

July 2014

Report Submitted by Director

Comment on the business results for the first six months of 2014

Medika Group („Group“) has realised total revenue in the first three months of 2014 in amount of HRK 1 billion 109.6 million which is by 6.24% lower comparing to the same period of previous year.

Sales revenues which amount to HRK 1 billion 92.6 million for the first six months of 2014 are by 6.04% lower comparing to the same period of previous year. Lower sales are influenced by lowering sales prices on the reimbursement list of drugs passed by HZZO. Namely, with the changes of the reimbursement list of drugs which occurred from second to fourth quarter of 2013 and in the first six months of 2014, sales prices were lowered multiple times. Also, from 01.01.2014 the sale prices of orthopaedic support devices are lowered as the new reimbursement list for orthopaedic support devices is effective from that date. Additionally, lower revenue from services also impacted decrease in sales. Revenue from services mainly relate to consignment fee which is by HRK 6.7 million lower comparing to the same period of previous year since consignment warehouses of the manufacturers that have headquarters in EU member countries are closed.

Share of sales revenues in the total revenue is 98.47% while in the same period of previous year it was 98.26%.

Other operating revenues which amount to HRK 7.8 million are lower comparing to the same period of previous year by 40.88%. Since the share of other operating revenues in total revenue was only 1.12% in the first six months of 2013, and in the first six months of 2014 is only 0.70%, this decrease is not that significant.

Out of the total sales revenues, 99.92% revenues are generated on domestic market, while 0.08% is generated on the foreign market. This structure has not changed in the first six months of 2014 comparing to the same period of previous year.

Material expenses amount to HRK 1 billion 6.5 million and are by 5.69% lower comparing to the same period of previous year. Since the operating expenses are declining faster, share of material expenses in the operating expenses is by 0.03% higher comparing to the same period of previous year and amounts to 93.15%.

Employee expenses are higher by 4.73% comparing to the same period of previous year and their share in the operating expenses has increased by 0.45%. This increase is influenced by higher number of employees.

Finance expenses have increased compared to the same period of previous year by 4.82% and their share in the total expenses has not significantly changed comparing to the same period of previous year and amounts 0.92%. This increase is the result of lower foreign exchange differences as a result of lower interest rates in the first six months of 2014 comparing to the same period of previous year.

Gross margin in the first six months of 2013 amounted to 10.31% while in the first six months of 2014 amounts to 10.04% which is decrease of 0.27%. Decrease is result of decreased net sales revenue which is by 6.04% lower while net cost of goods sold has decreased slower, that is 5.75%. Due to these movements, margin has decreased.

Gross profit (profit before taxation) amounts to HRK 19.1 million, while in the same period of previous year amounted to HRK 26.8 million, which is decrease of 28.89%. Lower gross profit is result of greater decrease of total income (decrease of 6.24% comparing to the same period of previous year) in relation to the decrease of total expenses (decrease of 5.71% comparing to the same period of previous year).

Operative earnings amount to HRK 19.9 million and are by HRK 10.0 million, or 33.47%, lower comparing to the same period of previous year because of higher decrease of operating revenues in the first six months of 2014 comparing to the same period of previous year (decrease of 6.43%, that is HRK 75.6 million) in relation to the decrease of operating expenses (decrease of 5.72%, that is HRK 65.6 million).

Realised net profit amounts to HRK 14.2 million.

Transactions with the related parties in the first six months of 2014 generated total revenue in amount of HRK 14.4 million, while in the same period of previous year total revenue amounted to HRK 14.8 million, which is decrease of 2.84%. Decrease is result of lower sales prices on reimbursement list of drugs.

Trade goods purchased from the related parties amount to HRK 93.4 million, while in the same period of previous year they amounted to HRK 106.6 million. Decrease is result of lower sales prices on reimbursement list of drugs.

Total assets are by 3.32% lower comparing to the beginning of the year which is mostly influenced by decrease of short term assets.

Long term assets have increased by 1.05% comparing to the beginning of the year. Long term intangible assets are higher comparing to the beginning of the year for HRK 2.5 million as a result of the purchase of new pharmacies. Long term tangible assets have increased comparing to the beginning of the year for HRK 1.8 million. This is result of new additions and increase in investment in new business centre Osijek.

Long term financial assets and deferred tax assets are almost at the same level comparing to the beginning of the year.

Short term assets amount to HRK 1 billion 487.8 million and are by HRK 69.9 million, or 4.49%, lower comparing to the beginning of the year. In the structure of short term assets receivables and financial assets have decreased, while inventory has increased.

Inventory has increased by HRK 53.7 million comparing to the beginning of the year due to the closing of consignment warehouse for the producer who has headquarters in EU member country. All merchandise form consignment warehouse was bought so the balance of this producer would be zero and consignment warehouse could be closed. Also, all merchandise has been bought from the supplier who closed importer warehouse.

Total receivables amount to HRK 1 billion 117.0 million and are lower for HRK 84.5 million, which is 7.03%, comparing to the beginning of the year. Trade receivables and receivables from related parties amount to HRK 1 billion 111.0 million and have decreased by 6.59% comparing to the beginning of the year.

Short term financial assets amount to HRK 32.2 million and mostly relates to given loans. Comparing to beginning of the year financial assets have decreased for HRK 18.2 million due to the repayment of the given loans.

Share capital has increased for HRK 40.8 million and amounts to HRK 135.0 million. Based on the decision passed by the General Assembly held 22 May 2014, Trade Court has passed the decision on inscribing the increase of share capital which was carried out by increasing the nominal value of the shares. Nominal value of the share was increased from HRK 3,120.00 to HRK 4,470.00.

Long term liabilities are higher comparing to the beginning of the year for HRK 10.8 million which is entirely influenced by increase in liabilities to banks and other financial institutions.

Short term liabilities amount to HRK 1 billion 412.7 million out of which HRK 1 billion 182.3 million relates to trade payables and liabilities to related parties, HRK 217.0 to indebtedness (HRK 216.3 million to short term loans and HRK 732 thousand to finance lease).

Trade payables and liabilities to related parties are lower for HRK 33.1 million comparing to the beginning of the year.

Total loans liabilities of the Group amount to HRK 237.1 million which is decrease of HRK 105.5 million comparing to the beginning of the year. Out of the total liabilities, HRK 20.8 million relates to long term loans and HRK 216.3 million to short term loans. In the second quarter cash inflow was better due to the recovery of health system (county hospitals) and it was used to lower the indebtedness.

Key events

Total pharmaceutical market in the first six months of 2014 has decreased comparing to the same period of previous year. At the same time, sales of Medika have decreased in smaller percentage comparing to the market decrease, so the market share has grown in 2014.

With the changes at the reimbursement list of drugs and at reimbursement list for orthopaedic support devices, sales prices were lowered which resulted in lower sales revenue and lower sales margin comparing to the same period of the previous year.

Based on the decision passed by the General Assembly, the increase of share capital was carried out. Share capital has increased for HRK 40.8 million and amounts to HRK 135.0 million.

Due to the better cash inflow as a result of recovery of county hospitals, the Company decreased indebtedness comparing to the beginning of the year.

In January 2014 ZU Ljekarne Hermed was bought and in March Ljekarna Elvira Štimac was merged with ZU Ljekarne Prima Pharme

Expected future development of the Company

The Company will continue with its core business: distribution of medications and medical products and will strongly develop operations with products that make the core business of the firm.

Development strategy of Prima Pharme is to expand network of pharmacies on whole territory of Croatia.

Treasury shares

As at 30.06.2014, Medika holds 1,155 treasury shares.

Subsidiaries and associates

The Company has 100% of ownership in subsidiary Zdravstvena ustanova Ljekarne Prima Pjarne and associate Litmus d.o.o. in which it holds 41.53% of ownership.

ZU Ljekarne Prima Pharme has 100% of ownership ZU Ljekarne Delonga, ZU Ljekarne Ines Škoko, ZU Ljekarne Atalić, ZU Ljekarne Hermed and associate ZU Ljekarne Jagatić in which it holds 49% of ownership.

During 2014 Ljekarna Elvira Štimac was merged with ZU Ljekarne Prima Pharme.

Related parties

The company with major voting rights, a parent company Mavota d.o.o. owns 47.38% of the Company and has 49.26% of shares with voting rights.

Pliva Hrvatska d.o.o., Zagreb owns 25.32% of the Company and has 26.33% of the voting rights. Given the share in the ownership and business transactions with the Company, Pliva Hrvatska has significant influence on the current operations of the Company.

Financial risks and exposure to price risk, credit risk, liquidity and cash flow risk

Within financial risks, foreign exchange risk is significant. The majority of Group's income is realised on domestic market in Croatian kuna. The Group's purchase of goods is predominantly realised on the foreign market. Furthermore, a part of the borrowings is linked to foreign currencies. The Group is therefore exposed to foreign exchange risk arising from various changes in foreign exchange rates mainly linked to the EUR.

As the Group has no significant interest-bearing assets, the Group's income and operating cash flows are substantially independent of changes in market interest rates.

The Group's interest rate risk arises from borrowings. Borrowings issued at variable rates expose the Group to cash flow interest rate risk. Borrowings issued at fixed rates expose the Group to fair value interest rate risk.

The Group does not use derivative instruments to actively hedge cash flow and fair value interest rate risk exposure. However, the Group continuously monitors changes in interest rates. Various scenarios are simulated taking into account refinancing, renewal of existing positions and alternative financing.

Price risk arises from a continuous decrease in the price of prescription medication on HZZO list and administrative approach in determining prices and margins of medication. To lower this risk, the Group focused on increase of variety of products which are not limited by law in respect of the price of the product.

Majority of the credit risk relates to trade receivables. Credit risk is higher when dealing with pharmacies, which have potential going concern issue. Hospitals which have longer collection period do not have a going concern issue and collection issue.

The most significant risk within market risks is a long collection period of receivables, especially HZZO and HZZO related receivables. Therefore, a significant amount of working capital is not available what has an influence on cash flows and timely settlement of the Group's liabilities. As these receivables are either dependent from or owned by State, risk of collection is not high, but this increases the need for future financing, which increases finance expenses.

Jasminko Herceg, dipl.oec.
Director


3 **Medika** d.d.
Z A G R E B Capraška

Appendix 1.

Reporting period:

1.1.2014.

to

30.6.2014

Quarterly financial statements TFI-POD

Registration number (MB): 03209741

Identification number of company (MBS): 080027531

Personal identification number (OIB): 94818858923

Issuer: **MEDIKA d.d.**

Postal code and city: 10000 ZAGREB

Address: **CAPRAŠKA 1**e-mail: medika.uprava@medika.hrweb page: www.medika.hr

Code and name of municipality/city: 133 ZAGREB

Code and county name: 21 GRAD ZAGREB Number of employees: 751
(end of reporting period)

Consolidated statements: YES NKD code: 4646

Consolidated entities (according to IFRS):

Headquarters:

MB:

ZU Ljekarne Prima Pharme Split 0694975

ZU Ljekarne Delonga Okrug Gornji 1605747

ZU Ljekarne Ines Škoko Zagreb 02708396

ZU Ljekarne Atalić Osijek 0845124

ZU Ljekarne Hermed Sisak 01252232

Bookkeeping service:

Contact person: **RADMILOVIĆ DIJANA**
(only name of the contact person)

Telephone number: 012412551 Fax: 012371441

e-mail: medika.uprava@medika.hrName: **HERCEG JASMINKO**
(authorised person)**Documentation for publishing:**

1. Financial statements (Balance sheet, Profit and loss account, Cash flow statements, Statements of changes in equity and Notes to financial statements)
2. Interim report,
3. Statement of Liability.

M.P.


Medika d.d.
 ZAGREB, Capraška 1

(signature of authorised person)

BALANCE SHEET
balance as at 30.6.2014.

Issuer: MEDIKA d.d.			
Description	AOP mark	Previous period	Current period
1	2	3	4
ASSETS			
A) RECEIVABLES FOR SUBSCRIBED BUT NOT PAID-IN CAPITAL	001		
B) NON-CURRENT ASSETS (003+010+020+029+033)	002	396.749.406	400.913.771
I. INTANGIBLE ASSETS (004 to 009)	003	188.717.677	191.168.563
1. Research and development	004		
2. Concessions, patents, licences, trademarks, software and other rights	005	114.946.894	113.377.362
3. Goodwill	006	71.933.150	75.937.947
4. Advances for intangible assets	007	106.987	106.988
5. Intangible assets under construction	008	1.730.646	1.746.266
6. Other intangible assets	009		
II. TANGIBLE ASSETS (011 to 019)	010	155.425.747	157.223.227
1. Land	011	15.994.715	15.994.715
2. Buildings	012	108.266.769	106.449.464
3. Equipment and machinery	013	4.780.720	4.599.707
4. Furniture, fittings and vehicles	014	10.274.130	9.874.532
5. Biological assets	015		
6. Advances for tangible assets	016	6.007.726	4.278.008
7. Tangible assets under construction	017	9.347.737	15.272.851
8. Other tangible assets	018	753.950	753.950
9. Investment property	019		
III. NON-CURRENT FINANCIAL ASSETS (021 to 028)	020	49.740.192	49.533.457
1. Investment in subsidiaries and associates	021	39.367.845	39.290.873
2. Loans to related parties	022		
3. Loans given to minority interest	023		
4. Loans given to participating parties	024		
5. Investment in securities	025		
6. Loans given, deposits and similar	026	10.372.347	10.242.584
7. Other non-current financial assets	027		
8. Investments at equity method	028		
IV. RECEIVABLES (030 to 032)	029	1.877.708	1.877.708
1. Receivables from related parties	030		
2. Receivables for credit sales	031		
3. Other receivables	032	1.877.708	1.877.708
V. DEFERRED TAX ASSET	033	988.082	1.110.816
C) CURRENT ASSETS (035+043+050+058)	034	1.557.718.738	1.487.841.793
I. INVENTORY (036 To 042)	035	239.296.937	292.991.278
1. Raw material	036	420.970	480.814
2. Work in progress	037		
3. Finished products	038		
4. Trade goods	039	237.687.713	287.109.410
5. Advances for inventories	040	1.188.254	5.401.054
6. Non-current assets available for sale	041		
7. Biological assets	042		
II. RECEIVABLES (044 to 049)	043	1.201.422.661	1.116.966.713
1. Receivables from related parties	044	17.413.787	17.690.399
2. Trade receivables	045	1.172.070.790	1.093.357.238
3. Receivables from participating parties	046		
4. Receivables from employees	047	419.044	408.681
5. Receivables from the state and other institutions	048	6.732.178	2.510.400
6. Other receivables	049	4.786.862	2.999.995
III. CURRENT FINANCIAL ASSETS (051 to 057)	050	50.405.113	32.253.175
1. Investment in subsidiaries and associates	051		
2. Loans to related parties	052		
3. Equity investments	053		
4. Loans given to participating parties	054		
5. Investment in securities	055		
6. Loans given, deposits and similar	056	50.405.113	32.253.175
7. Other financial assets	057		
IV. CASH IN BANK AND ON HAND	058	66.594.027	45.630.627
D) PREAPID EXPENSES AND ACCRUED INCOME	059	920.048	1.685.839
E) TOTAL ASSETS (001+002+034+059)	060	1.955.388.192	1.890.441.403
G) OFF BALANCE SHEET ITEMS	061	185.013.175	147.523.753

EQUITY AND LIABILITIES			
A) CAPITAL AND RESERVES (063+064+065+071+072+075+078)	062	421.223.079	435.396.179
I. SHARE CAPITAL	063	94.205.280	134.967.180
II. CAPITAL RESERVES	064	-9.243.180	-9.243.180
III. RESERVES FROM RETAINED EARNINGS (066+067-068+069+070)	065	88.587.743	88.587.744
1. Legal reserves	066	7.277.713	13.953.444
2. Reserves for treasury shares	067	60.000.000	53.324.269
3. Treasury shares	068	10.486.460	10.486.459
4. Statutory reserves	069		
5. Other reserves	070	31.796.490	31.796.490
IV. REVALUATION RESERVES	071		
V. RETAINED EARNINGS OR ACCUMULATED LOSS (073-074)	072	204.974.597	206.911.335
1. Retained earnings	073	204.974.597	206.911.335
2. Accumulated loss	074		
VI. PROFIT OR LOSS FOR THE PERIOD (076-077)	075	42.698.639	14.173.100
1. Profit for the period	076	42.698.639	14.173.100
2. Loss for the period	077		
VII. MAJORITY INTERESTS	078		
B) PROVISIONS (080 To 082)	079	800.366	800.366
1. Provisions for retirement, severance payment and similar	080	800.366	800.366
2. Tax provisions	081		
3. Other provisions	082		
C) NON-CURRENT LIABILITIES (084 to 092)	083	28.605.861	39.419.238
1. Liabilities to related parties	084		
2. Borrowings and deposits	085		
3. Liabilities to banks and other financial institutions	086	12.815.755	23.629.132
4. Liabilities for advances received	087		
5. Trade payables	088		
6. Liabilities for securities	089		
7. Liabilities to participating parties	090		
8. Other non-current liabilities	091		
9. Deferred tax liability	092	15.790.106	15.790.106
D) CURRENT LIABILITIES (094 to 105)	093	1.502.807.961	1.412.676.243
1. Liabilities to related parties	094	122.721.702	122.097.376
2. Borrowings and deposits	095		
3. Liabilities to banks and other financial institutions	096	333.785.448	217.025.742
4. Liabilities for advances received	097	420.814	109.142
5. Trade payables	098	1.026.425.417	1.060.172.221
6. Liabilities for securities	099		
7. Liabilities to participating parties	100		
8. Liabilities to employees	101	7.661.937	7.121.408
9. Liabilities for taxes and contributions	102	6.876.018	3.067.060
10. Dividend payables	103	1.034	1.034
11. Liabilities for non-current assets available for sale	104		
12. Other current liabilities	105	4.915.591	3.082.280
E) DEFERRED INCOME AND ACCRUED EXPENSES	106	1.950.925	2.149.377
F) TOTAL EQUITY AND LIABILITIES (062+079+083+093+106)	107	1.955.388.192	1.890.441.403
G) OFF BALANCE SHEET ITEMS	108	185.013.175	147.523.753
SUPPLEMENT TO BALANCE SHEET (for consolidated financial statements)			
A) CAPITAL AND RESERVES			
1. Attributable to equity holders	109	421.233.079	435.396.179
2. Attributable to minority interest	110		

Note 1.: Supplement to balance sheet is filled for consolidated financial statements.

PROFIT AND LOSS
for period from 1.1.2014. to 30.6.2014.

Issuer: MEDIKA d.d

Description	AOP mark	Previous period		Current period	
		Cumulative	Quarter	Cumulative	Quarter
1	2	3	4	5	6
I. OPERATING REVENUES (112+113)	111	1.176.040.626	593.423.539	1.100.454.872	557.229.037
1. Revenues from sale	112	1.162.817.603	584.774.069	1.092.637.128	553.590.158
2. Other operating revenues	113	13.223.023	8.649.470	7.817.744	3.638.879
II. OPERATING EXPENSES (115+116+120+124+125+126+129+130)	114	1.146.096.186	575.138.210	1.080.532.402	544.949.008
1. Change in value of work in progress and finished goods	115				
2. Material expenses (117 to 119)	116	1.067.285.567	538.206.395	1.006.515.263	510.464.259
a) Raw materials	117	6.444.236	3.029.270	6.694.480	3.465.749
b) Cost of goods sold	118	1.042.907.878	524.970.811	982.959.862	498.014.788
c) Other expenses	119	17.933.453	10.206.314	16.860.921	8.983.722
3. Employee expenses (121 to 123)	120	46.439.685	23.329.592	48.636.737	24.405.861
a) Net salaries	121	27.064.901	13.599.641	28.072.014	13.964.461
b) Tax and contributions from salaries	122	13.275.200	6.661.707	13.763.221	6.825.768
c) Contributions on salaries	123	6.099.584	3.068.244	6.801.502	3.615.632
4. Depreciation and amortization	124	7.832.931	3.841.485	6.714.595	2.885.260
5. Other expenses	125	18.188.003	9.760.738	12.776.575	7.193.628
6. Impairment (127+128)	126	6.350.000	0	5.889.232	0
a) of non-current assets (financial assets excluded)	127				
b) of current assets (financial assets excluded)	128	6.350.000		5.889.232	
7. Provisions	129				
8. Other operating expenses	130				
III. FINANCE INCOME (132 to 136)	131	7.399.509	7.075.272	9.167.884	7.506.779
1. Interests, foreign exchanges and dividend from related parties	132				
2. Interests, foreign exchanges and dividend from non-related parties	133	7.399.263	7.075.141	8.690.785	7.226.050
3. Share of profit from associate	134			477.099	280.729
4. Unrealised gains	135				
5. Other financial income	136	246	131		
IV. FINANCE EXPENSES (138 to 141)	137	10.530.129	3.534.092	10.022.641	4.661.938
1. Interests, foreign exchanges and dividend from related parties	138			154.072	79.510
2. Interests, foreign exchanges and dividend from non-related parties	139	10.530.129	3.534.092	9.868.569	4.582.428
3. Unrealised losses	140				
4. Other finance expenses	141				
V. SHARE OF PROFIT FROM ASSOCIATE	142				
VI. SHARE OF LOSS FROM ASSOCIATE	143				
VII. EXTRAORDINARY - OTHER INCOME	144				
VIII. EXTRAORDINARY - OTHER EXPENSES	145				
IX. TOTAL INCOME (111+131+142 + 144)	146	1.183.440.135	600.498.811	1.109.622.756	564.735.816
X. TOTAL EXPENSES (114+137+143 + 145)	147	1.156.626.315	578.672.302	1.090.555.043	549.610.946
XI. PROFIT OR LOSS BEFORE TAX (146-147)	148	26.813.820	21.826.509	19.067.713	15.124.870
1. Profit before tax (146-147)	149	26.813.820	21.826.509	19.067.713	15.124.870
2. Loss before tax (147-146)	150	0	0	0	0
XII. INCOME TAX	151	7.934.009	6.412.743	4.894.613	3.788.351
XIII. PROFIT OR LOSS FOR THE PERIOD (148-151)	152	18.879.811	15.413.766	14.173.100	11.336.519
1. Profit for the period (149-151)	153	18.879.811	15.413.766	14.173.100	11.336.519
2. Loss for the period (151-148)	154	0	0	0	0

SUPPLEMENT TO PROFIT AND LOSS (for consolidated financial statements)**XIV. PROFIT OR LOSS FOR THE PERIOD**

1. Attributable to equity holders	155				
2. Attributable to minority interest	156				

OTHER COMPREHENSIVE INCOME REPORT (for IFRS reporting)

I. PROFIT OR LOSS FOR THE PERIOD (= 152)	157	18.879.811	15.413.766	14.173.100	11.336.519
II. OTHER COMPREHENSIVE PROFIT/LOSS BEFORE TAX (159 to 165)	158	0	0	0	0
1. Exchange differences on translation of foreign operations	159				
2. Changes in revaluation reserves for non-current tangible and intangible assets	160				
3. Profit or loss from revaluation of financial assets available for sale	161				
4. Gains or losses from efficient cash flow hedging	162				
5. Gains or losses from efficient hedge of net investment abroad	163				
6. Share in other comprehensive profit/loss of associates	164				
7. Actuarial gains/losses on defined benefit plans	165				
III. TAX ON OTHER COMPREHENSIVE INCOME FOR THE PERIOD	166				
IV. NET OTHER COMPREHENSIVE PROFIT OR LOSS FOR THE PERIOD (158-166)	167	0	0	0	0
V. COMPREHENSIVE PROFIT OR LOSS FOR THE PERIOD (157+167)	168	18.879.811	15.413.766	14.173.100	11.336.519

APPENDIX to Other comprehensive income report (to be filled for consolidated financial statements)**VI. COMPREHENSIVE PROFIT OR LOSS**

1. Attributable to equity holders	169				
2. Attributable to minority interest	170				

STATEMENT OF CASH FLOW - Indirect method
for period from 1.1.2014. to 30.6.2014.

Issuer: MEDIKA d.d.			
Description	AOP mark	Previous period	Current period
1	2	3	4
CASH FLOW FROM OPERATING ACTIVITIES			
1. Profit before tax	001	26.813.820	19.067.713
2. Depreciation and amortisation	002	7.832.931	6.714.595
3. Increase of current liabilities	003		26.627.988
4. Decrease of current receivables	004	373.482.151	84.455.948
5. Decrease of inventories	005		
6. Other increase of cash flow	006		
I. Total increase of cash flow from operating activities (001 to 006)	007	408.128.902	136.866.244
1. Decrease of current liabilities	008	75.040.395	
2. Increase of current receivables	009		
3. Increase of inventories	010	52.938.144	53.694.341
4. Other decrease of cash flow	011	9.909.961	2.924.151
II. Total decrease of cash flow from operating activities (008 to 011)	012	137.888.500	56.618.492
A1) NET INCREASE OF CASH FLOW FROM OPERATING ACTIVITIES (007-012)	013	270.240.402	80.247.752
A2) NET DECREASE OF CASH FLOW FROM OPERATING ACTIVITIES (012-007)	014	0	0
CASH FLOW FROM INVESTING ACTIVITIES			
1. Proceeds from sale of tangible and intangible assets	015	944.596	142.085
2. Proceeds from sale of equity and debt securities	016		
3. Interest received	017	762.017	2.724.158
4. Dividends received	018		
5. Other proceeds from investing activities	019		
III. Total proceeds from investing activities (015 to 019)	020	1.706.613	2.866.243
1. Purchase of tangible and intangible assets	021	4.144.576	10.962.960
2. Purchase of equity and debt securities	022		
3. Other purchases resulting from investing activities	023		
IV. Total purchases resulting from investing activities (021 to 023)	024	4.144.576	10.962.960
B1) NET INCREASE OF CASH FLOW FROM INVESTING ACTIVITIES (020-024)	025	0	0
B2) NET DECREASE OF CASH FLOW FROM INVESTING ACTIVITIES (024-020)	026	2.437.963	8.096.717
CASH FLOW FROM FINANCING ACTIVITIES			
1. Proceeds from issuance of equity and debt securities	027		
2. Proceeds from borrowings	028	95.000.000	69.981.500
3. Other proceeds from financing activities	029		
V. Total proceeds from financing activities (027 to 029)	030	95.000.000	69.981.500
1. Repayments of borrowings	031	214.692.273	161.994.999
2. Dividends paid	032		
3. Repayments of finance lease	033	1.414.680	1.100.936
4. Purchase of treasury shares	034		
5. Other purchases resulting from financing activities	035		
VI. Ukupno novčani izdaci od finansijskih aktivnosti (031 to 035)	036	216.106.953	163.095.935
C1) NET INCREASE OF CASH FLOW FROM FINANCING ACTIVITIES (030-036)	037	0	0
C2) NET DECREASE OF CASH FLOW FROM FINANCING ACTIVITIES (036-030)	038	121.106.953	93.114.435
Total increase of cash flow (013 – 014 + 025 – 026 + 037 – 038)	039	146.695.486	0
Total decrease of cash flow (014 – 013 + 026 – 025 + 038 – 037)	040	0	20.963.400
Cash and cash equivalents at beginning of the period	041	19.540.285	66.594.027
Increase of cash and cash equivalents	042	146.695.486	
Decrease of cash and cash equivalents	043		20.963.400
Cash and cash equivalents at end of the period	044	166.235.771	45.630.627

STATEMENT OF CHANGES IN EQUITY
for period from **1.1.2014** to **30.6.2014**

Description	AOP mark	Previous period	Current period
1	2	3	4
1. Share capital	001	94.205.280	134.967.180
2. Capital reserves	002	-9.243.180	-9.243.180
3. Reserves from retained earnings	003	88.587.743	88.587.744
4. Retained earnings or accumulated loss	004	204.974.597	206.911.335
5. Profit or loss for the period	005	42.698.639	14.173.100
6. Revaluation of tangible assets	006		
7. Revaluation of intangible assets	007		
8. Revaluation of financial assets available for sale	008		
9. Other revaluation	009		
10. Total capital and reserves (AOP 001 to 009)	010	421.223.079	435.396.179
11. Foreign exchanges from the foreign investments	011		
12. Current and deferred tax (part)	012		
13. Cash flow hedge	013		
14. Cgchanges of accounting policies	014		
15. Correction of material mistakes from previous period	015		
16. Other changes of equity	016		
17. Total increase or decrease of equity (AOP 011 to 016)	017	0	0
17 a. Attributable to equity holders	018		
17 b. Attributable to minority interest	019		

Balances that decrease equity are presented with the minus
Data in AOP 001 to 009 are presented as the balance as at balance sheet date

Zagreb, 30 July 2014

Pursuant to the article 407. to 410. of the Capital market Law (Official Gazette 88/08 and 146/08) Director Jasminko Herceg provides

MANAGEMENT BOARD'S STATEMENT OF LIABILITY

Consolidated and unconsolidated financial statements of Medika d.d. have been prepared pursuant to the International Financial Reporting Standards (IFRS) and Croatian Accounting Law.

Consolidated and unconsolidated financial statements for the period from 01 January to 30 June 2014 present complete and fair view of assets and liabilities, profit and loss, financial position and operations of the Company and the Group.

The interim management report for the period from 01 January to 30 June 2014 gives true and fair presentation of development and results of the operations of the Company and the Group with description of significant risks and uncertainties for the Company and the Group.

Jasminko Herceg
Director


Medika d.d.
ZAGREB Capraška